Del Carpio OL

Language: Spanish
References: 17
Page: 666-680
PDF size: 221.14 Kb.

ABSTRACT

A narrative of the experience in Veracruz of COVID-19 is presented, in charge of a medical study group that includes various medical professionals, who in conjunction were kind enough to make contributions from the epidemiological plane, risk factors and severity of disease, as well as retrospective contributions regarding treatment options that at the time were emergency indications; we consider that this experience, very limited to a national geographic region, could be extended globally.

REFERENCES

1. Del Carpio-Orantes L. La evolución del tratamiento farmacológicocontra COVID-19. Med Int Mex 2021; 37 (5):842-845. https://doi.org/10.24245/mim.v37i5.4624.

2. Del Carpio-Orantes L, Dorantes-Nava CL. Diabetes mellitus2 y COVID-19, dos pandemias en simbiosis favorecidas porla obesidad. Med Int Méx 2021; 37 (3): 407-410.

3. Del Carpio-Orantes L, García-Méndez S, Contreras-SánchezER, González-Segovia O, et al. Caracterización clínica y delhemograma de pacientes con neumonía por COVID-19 enVeracruz, México. Rev Hematol Mex 2020; 21 (4): 205-209.https://doi.org/10.24245/rev_hematol.v21i4.4488.

4. Del Carpio-Orantes L, García-Méndez S, Solís-Sánchez I,Arnulfo Perfecto-Arroyo M, Patricia Moreno-Aldama N,Salvador Sánchez-Díaz J. Neurological symptoms in patientswith COVID-19 as manifestation of severity and prognosis,the case of anosmia and dysgeusia. J Neurol Sci 2021; 429:119899. doi:10.1016/j.jns.2021.119899.

5. Del Carpio-Orantes L, García-Méndez S, Sánchez-Díaz JS,et al. 345. Dermatological Manifestations in Patients withCOVID-19 Pneumonia in Veracruz, Mexico. Open ForumInfect Dis 2021; 8 (Suppl 1): S276-S277. doi:10.1093/ofid/ofab466.546.

6. Del Carpio-Orantes L, García-Méndez S, Sánchez-DíazJ, Rosas-Lozano A. Incidence of thrombotic events in apopulation affected by Covid-19 in a general hospital inVeracruz, Mexico. https://abstracts.isth.org/abstract/incidence-of-thrombotic-events-in-a-population-affectedby-covid-19-in-a-general-hospital-in-veracruz-mexico/.

7. Del Carpio-Orantes L, Mejía-Ramos SG, Aguilar-Silva A.COVID-19 and dengue coinfection in Veracruz, MexicoTravel Med Infect Dis 2022; 50: 102467. doi:10.1016/j.tmaid.2022.102467.

8. Del Carpio-Orantes L, Munguia-Sereno AE, Guerrero-Mancinas ZO, Aparicio-Sánchez EE, et al. 430. Frontlinedoctors infected with Covid-19 during a hospital outbreakin Veracruz, Mexico. Open Forum Infect Dis 2020; 7 (Suppl1): S281-S282. doi:10.1093/ofid/ofaa439.624.

9. Del Carpio-Orantes L, García-Méndez S, Hernández-Hernández SN, Rosas-Lozano AL, Munguia-Sereno AE,Guerrero-Mancinas ZO. 389. Neutrophil-lymphocyte index,platelet-lymphocyte index and systemic inflammationimmunityindex in patients with Covid-19 pneumonia inVeracruz, Mexico. Open Forum Infect Dis 2020; 7 (Suppl1): S263-4. doi: 10.1093/ofid/ofaa439.584.

10. Sánchez Díaz JS, Peniche Moguel KG, González EscuderoEA, Del Carpio Orantes L, Monares Zepeda E, PerezNieto OR, et-al. Glycosylated hemoglobin as a predictorof mortality in severe pneumonia by COVID-19. ExpertRev Respir Med 2021; 15 (8): 1077-1082. doi:10.1080/17476348.2021.1926988.

11. Carpio-Orantes LD, García-Méndez S, Martínez-Rojas M,Cortés-Román JS, Jiménez-Flores OR, Pascual-EpigmenioS, et al. Tocilizumab in patients with severe COVID-19pneumonia in Veracruz, Mexico. J Anesth Crit CareOpen Access 2020; 12 (5): 176-179. DOI: 10.15406/jaccoa.2020.12.00456.

12. Del Carpio-Orantes L, García-Méndez S, Zamudio-SeverinoGM, Sánchez-Díaz JS, Navarrete-Espinosa B, Rivera-ViñasMÁ, et al. Baricitinib in patients with severe pneumonia dueto COVID-19 in Veracruz, Mexico. Open Forum Infect Dis2021; 8 (Suppl 1): S350-1. doi: 10.1093/ofid/ofab466.697.

13. Carpio-Orantes LD, García-Méndez S, Sánchez-Díaz JS,Aguilar-Silva A, Contreras-Sánchez ER, Hernández-HernándezSN. Use of Fibroquel® (type I polymerized collagen)in patients with hypoxemic inflammatory pneumoniasecondary to COVID-19 in Veracruz, Mexico. J Anesth CritCare Open Access 2021; 13 (1): 69-73. DOI: 10.15406/jaccoa.2021.13.00471.

14. Méndez-Flores S, Priego-Ranero Á, Azamar-Llamas D, Olvera-Prado H, Rivas-Redonda KI, Ochoa-Hein E, Perez-OrtizA, Rendón-Macías ME, Rojas-Castañeda E, Urbina-Terán S,Septién-Stute L, Hernández-Gilsoul T, Aguilar-Morgan AA,Fernández-Camargo DA, Olivares-Martínez E, Hernández-Ramírez DF, Torres-Villalobos G, Furuzawa-Carballeda J.Effect of polymerised type I collagen on hyperinflammationof adult outpatients with symptomatic COVID-19. ClinTransl Med 2022; 12 (3): e763. doi: 10.1002/ctm2.763.

15. Del Carpio-Orantes L, García-Méndez S, Sánchez-DiazJS, Peniche-Moguel KG, Aparicio-Sánchez EE, Segura-Rodríguez OI, et al. Oral anticoagulation with rivaroxabanas thromboprophylaxis in patients recovered from COVID-19 pneumonia in Veracruz, Mexico. Res Pract ThrombHaemost 2021; 5 (Suppl 2). https://doi.org/10.15406/jaccoa.2021.13.00463.

16. Del Carpio-Orantes L. Los kits anti-COVID-19 ¿aportanalgún beneficio a la lucha contra la pandemia? Med IntMex 2022; 38 (2): 425-427. https://doi.org/10.24245/mim.v38i2.5893.

17. Del Carpio-Orantes L, Márquez-Rodriguez LA, García-PérezJL, et al. Experience of a Private Hospital in the Treatmentof COVID-19 Pneumonia in Veracruz, Mexico. Open ForumInfect Dis 2021; 8 (Suppl 1): S383-S384. doi:10.1093/ofid/ofab466.761.